Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...

Get top local stories in Southern California delivered to you every morning. Sign up for NBC LA's News Headlines newsletter.

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...

Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...

Get top local stories in DFW delivered to you every morning. >Sign up for NBC DFW's News Headlines newsletter. Merus: "It is still very, very speculative." Click here to download Jim Cramer's ...